Asia FX muted despite Fed cut bets; Japanese yen slides after PM Ishiba resigns
Investing.com - KeyBanc initiated coverage on Ypsomed Holding AG (SWX:YPSN) with an Overweight rating and a price target of CHF525.00 on Thursday.
The Swiss medical technology company, which recently completed its Diabetes Care divestiture in August 2025, has successfully transformed into a pure-play injectables company following four divestitures, with the Ypsotec transaction not yet closed.
KeyBanc estimates Ypsomed commands approximately 40% market share in the high-growth injectable market for pens and autoinjectors, ranking first in pen delivery and second in auto-injectors, with plans to enter the U.S. market.
The company is investing CHF 1.1 billion to expand annual production capacity from 300 million to 1 billion units between fiscal years 2026 and 2030, representing a capacity expansion CAGR of 27%, with customers committing an additional CHF 400 million to support this growth.
KeyBanc expects Ypsomed to achieve mid-teens revenue growth in the near term, accelerating to 20% growth in fiscal year 2028 and beyond, outpacing most life science peers by 2-3 times, driven by strong demand for injectable devices for biologic drugs and GLP-1 medications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.